| Literature DB >> 35326753 |
Andrea Polistena1,2, Francesco Paolo Prete3, Stefano Avenia2, Giuseppe Cavallaro1, Giovanna Di Meo3, Alessandro Pasculli3, Fabio Rondelli2, Alessandro Sanguinetti2, Lucia Ilaria Sgaramella3, Nicola Avenia2, Mario Testini3, Angela Gurrado3.
Abstract
Thyroid and parathyroid surgery are considered clean procedures, with an incidence of surgical site infection (SSI) after thyroidectomy ranging from 0.09% to 2.9%. International guidelines do not recommend routine antibiotic prophylaxis (AP), while AP seems to be employed commonly in clinical practice. The purpose of this systematic review is analyzing whether the postoperative SSI rate in thyroid and parathyroid surgery is altered by the practice of AP. We searched Pubmed, Scopus, the Cochrane Library, and Web of Science (WOS) for studies comparing AP to no preoperative antibiotics up to October 2021. Data on the SSI rate was evaluated and summarized as relative risks (RR) with 95% confidence intervals (95% CI). Risk of bias of studies were assessed with standard methods. Nine studies (4 RCTs and 5 nRCTs), including 8710 participants, were eligible for quantitative analysis. A meta-analysis showed that the SSI rate was not significantly different between AP and no preoperative antibiotics (SSI rate: 0.6% in AP vs. 2.4% in control group; RR 0.69, 0.43-1.10 95% CI, p = 0.13, I2 = 0%). A sensitivity analysis and subgroup analysis on RCTs were consistent with the main findings. Evidence of low quality supports that AP in thyroid and parathyroid surgery produce similar SSI rates as to the absence of perioperative antibiotics.Entities:
Keywords: SSI; antibiotic prophylaxis; parathyroid; surgery; thyroid
Year: 2022 PMID: 35326753 PMCID: PMC8944446 DOI: 10.3390/antibiotics11030290
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1PRISMA flow chart of search results and selection of studies.
Study design, characteristics of populations, interventions and outcomes in the included studies.
| Author, Publication Year, Country | Study Design | Inclusion Criteria | Time Interval | No. Pt | Mean Age, y | Male, % | Procedure | Thyroid Pathology | Radical Neck Dissection, % | Drain, % | Operative Time, min | Lenght of Stay, days | Antibiotic Prophylaxis | SSI, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| De Palma, 2013, Italy | Case control, Multicenter | Thyroid surgery within the study interval | 1 January 2009–31 December 2011 | 2926 | 52+/−14.6 | 22.3 | TT, n-TT, TL | Benign and malignant (15%-DTC, MTC, anaplastic ca) | NA | 91.4 | NA | NA | 1132 | 4/1132, 0.35 |
| 1784 | 14/1784, 0.78 | |||||||||||||
| Uruno, 2015, Japan | RCT, Single Center | Clean neck surgery for thyroid or parathyroid disease (Excl.: no consent, sternotomy, resection of trachea, larynx, pharynx, oesophagus, penicillin allergy) | November 2010–April 2012 | 2164 | 52+/−15.1 | 15.6 | TT, n-TT, TL, PTX (4%) | Benign and malignant | 9 | NA | 74.7+/−38.1 | 4 | 1082 (541 Piperacillin, 541 Cefazolin) | 1/1082, 0.09 |
| 52+/−14.7 | 14.9 | 8.7 | 76.1+/−34.0 | 1082 | 3/1082, 0.28 | |||||||||
| Lee, 2017, Korea | Retrospective cohort, Single Center | Thyroid surgery, single Institution, single surgeon (Excl.: endoscopic, robotic surgery) | January 2013–June 2013 | 1895 | 44+/−11.4 | 21.7 | TT, lt-TT | Malignant (89% CCND, 11% LND) | 12.2 | 100 | 108.6+/−56.6 | NA | 1303 | 8/1303 |
| July 2013–December 2013 | 43.6+/−10.5 | 26.4 | 9.6 | 100 | 99.0+/−44.0 | 592 | 2/592 | |||||||
| Vamvakidis, 2017, Greece | Retrospective cohort, Single Center | Clean neck surgery | 2010–2014 | 807 | 49 | 20.3 | TT, PTX | Benign and malignant (45%-PTC, MTC, other) | 8.8 | NA | 168.5 | NA | 518 | 2/518, 0.4 |
| 289 | 4/289, 1.4 | |||||||||||||
| Moskalenko, 2018, USA | Retrospective cohort, Single Center | Thyroid or parathyroid surgery, data from NSQIP database, single center | November 2007–June 2015 | 534 | 59.6 | 23.2 | TT, TL, PTX (32.9%) | NA | NA | 7/151, 5 | 79 | NA | 141 | 1/141, 0.7 |
| 60.6 | 21.7 | 4/393, 1 | 105 | 393 | 0/393, 0 | |||||||||
| Salem, 2018, Sweden | Nested Case-Control, Multicenter | Thyroid surgery, data from SQRTPA database | 2004–2010 | 218 ** | 53 | 26.6 | TT, TL | Benign and Malignant | 2.5 | NA | NA | NA | 9 | 3/9,33.9 |
| 19.2 | 169 | 75/16944.3 | ||||||||||||
| Shkedy, 2018, Israel | RCT, Single Center | Clean revision H&N surgery, >18 years, no preop indication to AP (Excl.: irradiation, other factors requiring abx, tracheostomy, concurrent infection, penicillin allergy, immunosuppression,) | January 2014–January 2017 | 53 | 54.5+/−15.7 | 19.4 | ND, TT, TL, PTX (3.7%), PTD (3.7%) | NA | 32.2 | NA | NA | 3.6+/−1.1 | 31 | 2/31, 6.5 |
| 55.5+/−14.2 | 36.4 | 13.6 | 3.5+/−1.1 | 22 | 4/22, 18.2 | |||||||||
| Vathul, 2018, India | RCT, Single Center | Benign (FNAC), TT or TL, >18 <70 years, not Immunocompromised | NA | 102 | NA | NA | TT, TL | Benign | - | 50 | NA | 4 | 50 | 2/50, 4 |
| 52 | 3 | 52 | 2/52, 3.8 | |||||||||||
| Rao, 2021, India | RCT, Single Center | Benign thyroid disease, >16 <80 years, consent (Excl.: diabetes, infective or hematologic disease, other infection, BMI > 25, steroids or immunosuppression, malignancy, drain > 70 mL) | 2021 | 67 | 44.33+/−7.9 | NA | TT, TL | Benign | - | 33 | NA | NA | 33 | 3/33, 9 |
| 43.11+/−6.9 | 34 | 34 | 3/34, 8.8 |
For each study overall data are presented; split data in the upper row are relative to antibiotic prophylaxis, in lower row to control group (no antibiotic prophylaxis). NA: data not available; Abx: antibiotics; SSI: Surgical Site Infection; AP: antibiotic prophylaxis; H&N: head and neck; NSQIP: National Surgical Quality Improvement Program; SQRTPA: Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal Surgery; TT: Total Thyroidectomy; n-TT: near Total Thyroidectomy; TL: Thyroid lobectomy: lt-TT: less than TT; CCND: Central Compartment Node Dissection; LND: Lateral Node Dissection; ND: neck dissection; PTX: parathyroidectomy; PTD: parotidectomy; ** 109 SSI and 109 controls matched out of 9494.
Characteristics of antibiotic prophylaxis, definition of SSI and follow-up interval.
| Author, Publication Year, Country | Preoperative Patient Skin Prepping | Antibiotic Prophylaxis | Timing | Route | Follow Up | SSI Definition |
|---|---|---|---|---|---|---|
| De Palma, 2013, Italy | NA | cephalosporins or aminopenicillins ± beta lactamase inhibitors | NA | IV | NA | NA |
| Uruno, 2015, Japan | Chlorhexidine gluconate solution | Piperacillin, 2 g or Cefazolin, 1 g | Immediately after intubation—if operating time > 3 h, further dose | IV | 30 days | CDC guidelines for incisional SSI |
| Lee, 2017, Korea | NA | NA | NA | NA | 30 days | CDC guidelines for incisional SSI |
| Vamvakidis, 2017, Greece | NA | Cefuroxime | NA | IV | NA | NA |
| Moskalenko, 2018, USA | At the discretion of the operating surgeon (Povidone-iodine used in 96% of patients, or Chloraprep 3.2%) | Cefazolin, Vancomycin, or Clindamycin | NA | IV | 30 days | NSQIP criteria (CDC’s definitions for superficial incisional infection, deep incisional infection) |
| Salem, 2018, Sweden | NA | NA | NA | NA | six weeks | Local wound complication, SQRTPA criteria |
| Shkedy, 2018, Israel | NA | IV Cefazolin, 1 g (2 g if BMI > 40) | 30–60 min before surgery | IV | 30 days | CDC guidelines for incisional SSI |
| Vathul, 2018, India | NA | 3rd Gen Cephalosporins | 3–4 doses, NA | IV | three months | NA |
| Rao, 2021, India | Povidone iodine-Betadine for 2–5 min then 0.25 g benzalkonium chloride and 70 g 96% alcohol in concentric circles from the incision site (3 times) | Cefuroxime 1 g | Three doses eight hourly, from induction of anaesthesia | IV | six weeks | Southampton grading scale |
CDC: Centers for Disease Control and Prevention; SSI: Surgical Site Infection; NSQIP: National Surgical Quality Improvement Program; SQRTPA: Scandinavian Quality Register for Thyroid, Parathyroid and Adrenal Surgery; IV: intravenous. 2.3. Risk of bias.
Figure 2Risk of bias graphic and summary for the included RCTs.
Minors scores for comparative studies.
| Author, Publication Year, Country | Study Design | Clearly Stated Aim | Inclusion of Consecutive Patients | Prospective Collection of Data | Endpoints Appropriate to the Aim of the Study | Unbiased Assessment of the Study Endpoint | Follow-Up Period Appropriate to the Aim of the Study | Loss to Follow-Up Less Than 5% | Prospective Calculation of the Study Size | An Adequate Control Group | Contemporary Groups | Baseline Equivalence of Groups | Adequate Statistical Analyses | Score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| De Palma, 2013, Italy | Case control, Multicenter | 2 | 0 | 2 | 2 | 0 | 0 | 2 | 0 | 2 | 2 | 1 (DRAIN) | 2 | 15 |
| Lee, 2017, Korea | Retrospective cohort, Single Center | 2 | 2 | 0 | 2 | 0 | 0 | 2 | 0 | 2 | 0 | 2 | 2 | 14 |
| Vamvakidis, 2017, Greece | Retrospective cohort, Single Center | 2 | 2 | 0 | 2 | 0 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 18 |
| Moskalenko, 2018, USA | Retrospective cohort, Single Center | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 2 | 2 | 2 | 2 | 22 |
| Salem, 2018, Sweden | Matched Case-Control, Multicenter | 2 | 2 | 2 | 2 | 1 | 2 | 1 | 0 | 2 | 2 | 2 | 2 | 20 |
Per-item score: 2 = adequate; 1 = reported but not adequate; 0 = not reported (Overall score: zero = poor, 24 = good). MINORS: methodological index for nonrandomized studies.
Figure 3Forest plot for SSI rate in AP group vs. control group (no AP)—All studies.
Figure 4Forest plot for SSI rate in AP group vs. control group (no AP)—RCTs only.